NCT00287664

Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study

• Status: Suspended
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (planned)
• Sponsor: Hospital Clinic of Barcelona · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous studies are pilot studies and they are not able to give information about an improvement in survival. This comparative randomized study was delineated to test the efficacy of terlipressin on survival.

Detailed description

Phase 3

Conditions

• Cirrhosis
• Hepatorenal Syndrome

Interventions

Type	Name	Description
DRUG	terlipressin

Timeline

• Start date: 2002-02-01
• Completion: 2006-09-01
• First posted: 2006-02-07
• Last updated: 2007-04-11

Locations

1 site across 1 country: Spain